<h4>Aims</h4>To evaluate whether treatment with LY2409021, a novel, selective glucagon receptor antagonist, is associated with changes in hepatic fat and other safety variables related to the benefit-risk profile for chronic use in patients with type 2 diabetes (T2D).<h4>Methods</h4>Safety and effic...
No comments yet
Be the first to share your thoughts!